Feinberg L, Travis W D, Ferrans V, Sato N, Bernton H F
Mayo Medical School, Rochester, Minnesota.
Am Rev Respir Dis. 1990 Feb;141(2):505-8. doi: 10.1164/ajrccm/141.2.505.
A report is presented of an 85-yr-old woman who developed severe pulmonary fibrosis while receiving tocainide for treatment of ventricular arrhythmias. Severe bilateral interstitial fibrosis was documented in this patient by open lung biopsy and at autopsy. Review of the literature revealed other cases with an association between the use of tocainide and the development of pulmonary complications such as pulmonary fibrosis and interstitial pneumonitis, and suggested that clinical improvement occurs when the correct diagnosis is made early and tocainide therapy is stopped immediately. Because tocainide is currently being widely used for the treatment of ventricular arrhythmias, the pulmonary status of patients receiving tocainide should be monitored closely. Hopefully, awareness of this potential complication of tocainide therapy will minimize the number of cases of serious pulmonary toxicity.
报告了一名85岁女性在接受妥卡尼治疗室性心律失常时发生严重肺纤维化的病例。通过开胸肺活检和尸检证实该患者存在严重的双侧间质性纤维化。文献回顾显示,其他病例也有使用妥卡尼与发生肺纤维化和间质性肺炎等肺部并发症之间的关联,并表明早期做出正确诊断并立即停止妥卡尼治疗后临床症状会改善。由于妥卡尼目前被广泛用于治疗室性心律失常,因此应密切监测接受妥卡尼治疗患者的肺部状况。希望对妥卡尼治疗这一潜在并发症的认识能减少严重肺毒性病例的数量。